

TRANSGENOMIC INC  
Form 8-K  
September 23, 2016

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **September 20, 2016**

**Transgenomic, Inc.**

(Exact Name of Registrant as Specified in Charter)

|                                 |                  |                   |
|---------------------------------|------------------|-------------------|
| <b>Delaware</b>                 | <b>000-30975</b> | <b>91-1789357</b> |
| (State or Other Jurisdiction of | (Commission      | (IRS              |
| Incorporation)                  | File Number)     | Employer          |
|                                 |                  | Identification    |
|                                 |                  | No.)              |

**12325 Emmet Street, Omaha, NE 68164**

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: **(402) 452-5400**

N/A

(Former Name, or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appoint of Principal Officers.**

On September 20, 2016, Leon F. Richards, the Chief Accounting Officer of Transgenomic, Inc. (the “Company”), submitted his resignation from the Company, effective September 30, 2016. Mr. Richards joined the Company as Controller in November 2012 and has served as Chief Accounting Officer and Controller since November 2014. His resignation was not due to any disagreement with the Company. No replacement has been named for Mr. Richards. In the interim, Paul Kinnon will continue as the Company’s President and Chief Executive Officer, Chief Financial Officer (Principal Financial Officer) and Secretary.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Transgenomic, Inc.**

By: /s/ Paul Kinnon  
Paul Kinnon  
President and Chief Executive Officer

Date: September 23, 2016